EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Initial Experience with MR-Guided or CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer

Marc Vincent N Barcelona iD, Noelia Sanmamed Salgado iD, Enrique Gutierrez Valencia, Alejandro Berlin, Rachel Glicksman iD, Charles Catton, Andrew McPartlin, Jeff D Winter iD, Jennifer Dang, Vickie Kong iD, Yangqing Deng, Peter Chung iD

Current Oncology · 2026

DOI: 10.3390/curroncol33090504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von Marc Vincent N Barcelona und 11 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiosurgery, Tomography, X-Ray Computed, Radiotherapy, Image-Guided. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report early toxicity outcomes after institutional implementation of prostate SBRT using 42.7 Gy in seven fractions delivered with either MR-guided adaptive SBRT (MRgSBRT) or CT-guided non-adaptive SBRT (CTgSBRT). Between July 2019 and May 2023, 216 patients received this regimen. Genitourinary (GU) and gastrointestinal (GI) toxicities were retrospectively assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Most patients had intermediate-risk disease (86%), and 14% had high-risk disease. Median prostate volume was 40 mL, and median baseline International Prostate Symptom Score (IPSS) was 8 among patients with available data. MRgSBRT and CTgSBRT were used in 100 (46%) and 116 (54%) patients, respectively. At a median follow-up of 19 months, 12- and 24-month grade ≥ 2 GU toxicity rates were 20.0% and 18.2%, while grade ≥ 2 GI toxicity rates were 3.5% and 3.6%, respectively. No statistically significant platform-related differences were detected; however, these comparisons were exploratory and potentially confounded by nonrandomized platform selection, treatment era, rectal-spacer use, adaptive workflow and differing PTV margins. On univariable analysis, baseline GU symptoms were associated with higher 12-month grade ≥ 2 GU toxicity (OR, 3.68; 95% CI, 1.52–10.37; p = 0.007), while prostate-volume category was not significantly associated with this endpoint.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiosurgeryTomography, X-Ray ComputedRadiotherapy, Image-GuidedMagnetic Resonance ImagingHumansMaleRetrospective StudiesAgedMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

MR-guided radiation therapyadaptive radiotherapyprostate cancerstereotactic ablative body radiotherapystereotactic body radiation therapyultrahypofractionation

Autor:innen und Institutionen

  • Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada.
  • Department of Radiotherapy, Jose R. Reyes Memorial Medical Center, San Lazaro Compound, Rizal Ave. Sta Cruz, Manila 1003, Philippines.
  • Department of Radiation Oncology, Manila Doctors Hospital, 667 United Nations Avenue, Ermita, Manila 1000, Philippines.
  • Department of Radiation Oncology, San Carlos Hospital, Calle del Prof Martín Lagos, s/n, 28040 Madrid, Spain.
  • Department of Radiation Oncology, Dr. H. Bliss Murphy Cancer Centre, Memorial University of Newfoundland, 300 Prince Philip Drive, St. John's, NL A1B 3V6, Canada.
  • Department of Biostatistics, University Health Network, 610 University Ave, Toronto, ON M5G 2M9, Canada.

ORCID-Profile: Marc Vincent N Barcelona, Noelia Sanmamed Salgado, Rachel Glicksman, Jeff D Winter, Vickie Kong, Peter Chung

Zitieren

APA

Barcelona, M. V. N., Sanmamed Salgado, N., Valencia, E. G., Berlin, A., Glicksman, R., Catton, C., McPartlin, A., Winter, J. D., Dang, J., Kong, V., Deng, Y., & Chung, P. (2026). Initial Experience with MR-Guided or CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer. Current Oncology. https://doi.org/10.3390/curroncol33090504

Vancouver

Barcelona MVN, Sanmamed Salgado N, Valencia EG, Berlin A, Glicksman R, Catton C, et al. Initial Experience with MR-Guided or CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer. Current Oncology. 2026. doi:10.3390/curroncol33090504

BibTeX
@article{Barcelona2026,
  author = {Barcelona, Marc Vincent N and Sanmamed Salgado, Noelia and Valencia, Enrique Gutierrez and Berlin, Alejandro and Glicksman, Rachel and Catton, Charles and McPartlin, Andrew and Winter, Jeff D and Dang, Jennifer and Kong, Vickie and Deng, Yangqing and Chung, Peter},
  title = {Initial Experience with MR-Guided or CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer},
  journal = {Current Oncology},
  year = {2026},
  doi = {10.3390/curroncol33090504}
}
Kostenlos starten →